°Ç¼± ȯÀÚ¿¡¼ Infliximab (Remicade¨Þ) Åõ¿© ÈÄ ¹ß»ýÇÑ ½Å±â´É ÀúÇÏ 1¿¹
Development of Renal Disorder in a Patient Receiving Infliximab (Remicade¨Þ) for Psoriasis
´ëÇÑÇǺΰúÇÐȸÁö 2014³â 52±Ç 7È£ p.494 ~ p.497
±è´ëÈ«(Kim Dae-Hong) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¼º¸ðº´¿ø ÇǺΰúÇб³½Ç
ÀÌÁöÇö(Lee Ji-Hyun) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¼º¸ðº´¿ø ÇǺΰúÇб³½Ç
±èÅÂÀ±(Kim Tae-Yoon) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¼º¸ðº´¿ø ÇǺΰúÇб³½Ç
Abstract
Infliximab (Remicade¨Þ) has been used for treating many chronic inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, Crohn`s disease, and psoriasis. Complications such as infusion reaction and infection in infliximab therapy have been reported, but renal complications are rare. We present data on a patient with psoriasis for 15 years who developed new onset renal disorders (IgA nephropathy, acute tubulointerstitial nephritis, acute tubular necrosis) after treatment with infliximab (duration of therapy: 12 months, 8 times). Because the patient with psoriasis receiving infliximab may develop new onset renal disorders, we recommend the evaluation of renal function.
Å°¿öµå
Chronic inflammatory diseases, Infliximab, Renal disorder
KMID :
0363220140520070494
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)